Amgen cholesterol drug cuts risk of first cardiac event by 25%

By Deena Beasley (Reuters) -Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events ...
BioSpace

Amgen’s Repatha Cuts Risk of First Heart Attack by 36% in Phase III Trial

The cholesterol-lowering drug is part of a suite of medicines that also includes MariTide and that Amgen Chief Medical ...
Lodi News-Sentinel

AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL

Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® ...
U.S. News & World Report

Amgen to Sell Cholesterol Drug at 60% Discount to Cash-Paying US Patients

LOS ANGELES (Reuters) -Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol-lowering medication Repatha at a discounted cash price, becoming the latest pharmaceutical company to ...
Becker's Hospital Review

Amgen launches direct-to-patient program to sell cholesterol drug at 60% discount

Amgen launched a direct-to-patient program Oct. 6 to offer its cholesterol medication Repatha at a reduced price. The AmgenNow program will provide Repatha for $239 per month — nearly 60% below the ...